Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes

Radiother Oncol. 2023 Nov:188:109892. doi: 10.1016/j.radonc.2023.109892. Epub 2023 Sep 1.

Abstract

Background and purpose: Clinically localized Merkel cell carcinoma (MCC) has been associated with high rates of disease relapse. This study examines how primary tumor anatomic site drives patterns of care and outcomes in a large cohort treated in the contemporary era.

Materials and methods: Patterns of care and associated outcomes were evaluated for clinically Stage I-II MCC patients treated at our institution with adjuvant radiation therapy (RT) to the primary site and/or regional nodal basin as a component of their curative intent therapy between 2014-2021.

Results: Of 80 patients who met inclusion criteria, the primary tumor anatomic site was head and neck (HN) for 42 (53%) and non-head and neck (NHN) for 38 (47%). Primary tumor risk factors were similar between cohorts. Fewer patients with HN tumors had wide local excision (WLE; HN-81% vs. NHN-100% p < 0.01). Of those undergoing WLE, patients with HN tumors received higher dose adjuvant RT (>50 Gy: HN-70% vs. NHN-8%; p < 0.01). Patients with HN tumors were less likely to undergo sentinel lymph node biopsy (HN-62%vs. NHN-100%; p < 0.01) and more likely to have elective nodal RT (HN-48% vs. NHN-0%). Despite varying management strategies, there was no significant difference in local recurrence-free survival (3-yr LRFS HN-94% vs. NHN-94%; p = 0.97), nodal recurrence-free survival (3-yr NRFS HN-89% vs. NHN-85%; p = 0.71) or overall recurrence-free survival (3-yr RFS 73% HN vs. 80% NHN; p = 0.44).

Conclusions: Among patients with primary MCC who had RT as a component of their initial treatment strategy, anatomically-driven heterogeneous treatment approaches were associated with equally excellent locoregional disease control.

Keywords: Anatomic site; Merkel cell carcinoma; Radiation therapy; Surgery.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Carcinoma, Merkel Cell* / mortality
  • Carcinoma, Merkel Cell* / pathology
  • Carcinoma, Merkel Cell* / radiotherapy
  • Carcinoma, Merkel Cell* / therapy
  • Female
  • Head and Neck Neoplasms* / mortality
  • Head and Neck Neoplasms* / pathology
  • Head and Neck Neoplasms* / radiotherapy
  • Head and Neck Neoplasms* / therapy
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Radiotherapy, Adjuvant
  • Retrospective Studies
  • Skin Neoplasms* / mortality
  • Skin Neoplasms* / pathology
  • Skin Neoplasms* / radiotherapy
  • Skin Neoplasms* / therapy
  • Treatment Outcome